{
  "content": ". 17.    Lee S, Anglade MW, Pham D, Pisacane R, Kluger J, Coleman CI. Cost-effectiveness of rivaroxaban compared to warfarin for stroke prevention in atrial fibrillation. Am J Cardiol 2012;110:845-51. 18. Oâ€™Brien CL, Gage BF. Costs and effectiveness of ximelagatran for stroke prophylaxis in chronic atrial fibrillation. JAMA 2005;293: 699-706. 19. Shah SV , Gage BF. Cost-effectiveness of dabigatran for stroke pro-phylaxis in atrial fibrillation. Circulation 2011;123:2562-70. 20.   Kim H, Kim H, Cho SK, Kim JB, Joung B, Kim C. Cost-effective-ness of rivaroxaban compared to warfarin for stroke prevention in atrial fibrillation. Korean Circ J 2019;49:252-63. 21.   Wyse DG, Waldo AL, DiMarco JP, Domanski MJ, Rosenberg Y, Schron EB, et al",
  "source": "https://pdfs.semanticscholar.org/798d/e6aa4ebeb8836fdffb27a98ab4195330069c.pdf",
  "chunk_id": "a23e9b18-1835-44df-92bb-1acd491fa656",
  "similarity_score": 0.2533750534057617,
  "query": "cost effectiveness economic analysis amiodarone beta-blockers atrial fibrillation healthcare costs hospitalization reduction",
  "rank": 38,
  "title": "Cost-effectiveness of rate- and rhythm-control drugs for treating atrial fibrillation in Korea",
  "authors": "Min Kim, Woojin Kim, Changsoo Kim, Boyoung Joung",
  "year": "2019",
  "journal": "Yonsei Medical Journal",
  "reference": "Kim, M., Kim, W., Kim, C., & Joung, B. (2019). Cost-effectiveness of rate- and rhythm-control drugs for treating atrial fibrillation in Korea. Yonsei Medical Journal, 60(12), 1157-1163. https://doi.org/10.3349/ymj.2019.60.12.1157",
  "doi": "10.3349/ymj.2019.60.12.1157",
  "chunk_index": 55,
  "total_chunks": 62,
  "retrieved_at": "2025-07-24T21:58:16.915885"
}